Shandong Quanzhong Biomedical Technology Co. Ltd. has synthesized monoamine transmitter reuptake inhibitors reported to be useful for the treatment of neurological disorders, depression, autism, pain, substance abuse and dependency, epilepsy, osteoporosis and metabolic diseases, among others.

Hangzhou Baicreat Pharma-Tech Co. Ltd. has disclosed oxamide compounds acting as signal transducer and activator of transcription 6 (STAT6) inhibitors reported to be useful for the treatment of cancer and inflammatory disorders.

Zhuhai United Laboratories Co. Ltd. has described β-lactamase (bacterial) inhibitors reported to be useful for the treatment of bacterial infections.

Mindrank Therapeutics (Suzhou) New Drug Research & Development Co. Ltd. has divulged molecular glue degraders comprising cereblon (CRBN) ligands acting as dual eukaryotic peptide chain release factor GTP-binding subunit ERF3A (GSPT1) and casein kinase 1 isoform α (CSNK1A1) degradation inducers. They are reported to be potentially useful for the treatment of cancer, Alzheimer’s disease, inflammatory disorders, autoimmune diseases and metabolic diseases.

Hutchmed Ltd. has identified antibody-drug conjugates comprising an antibody or antigen binding fragment covalently linked to a GTPase RAS or KRAS inhibitor through a linker reported to be useful for the treatment of cancer.

Hangzhou Zhongmei Huadong Pharmaceutical Co. Ltd. has synthesized GTPase KRAS wild-type and/or its mutant inhibitors reported to be useful for the treatment of cancer.

Yichang Humanwell Pharmaceutical Co. Ltd. has disclosed morphinan derivatives acting as κ-opioid receptor agonists reported to be useful for the treatment of pain and pruritus.

Shanghai Phrontline Biopharma Co. Ltd. has described antibody-drug conjugates comprising an antibody or antigen-binding fragment targeting HER2 (erbB2) covalently linked to a cytotoxic drug through a linker reported to be useful for the treatment of cancer.

Adlai Nortye Biopharma Co. Ltd. and Adlai Nortye Pte Ltd. have divulged GTPase KRAS (mutant) inhibitors reported to be useful for the treatment of cancer, inflammatory diseases and immunological disorders.

Idorsia Pharmaceuticals Ltd. has identified aryl sulfone and sulfanone derivatives acting as orexin OX2 receptor (HCRTR2) agonists reported to be useful for the treatment of eating disorders, fatigue, Kleine-Levin syndrome, narcolepsy, obesity, pain, and psychiatric and inflammatory disorders, among others.